Autobahn Therapeutics

Improving life health for people affected by CNS disorders

San Diego, United States · Founded 2017 · $208.7M raised

Employees
11–50
Founded
2017
Business Model
B2B
Total Funding
$208.7M
Last Round
$100.0M Series CJul 2024
Rounds
3

About

Autobahn Therapeutics is a clinical-stage biotechnology company developing next-generation medications for central nervous system (CNS) disorders, including neuropsychiatric and neuroimmunologic conditions. Its lead candidate ABX-002 is a thyroid hormone receptor beta agonist in Phase 2 trials for bipolar depression, guided by a brain-targeting chemistry platform and biomarker-driven development.

Summary

Autobahn Therapeutics is a Life Sciences company based in San Diego, United States, founded in 2017. It has raised $208.7M in total across 3 rounds, most recently a $100.0M Series C round in Jul 2024. Investors include ARCH Venture Partners, Cowen Healthcare Investments and Newpath Management.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

Series CSeries CJul 2024
$100.0M

Sign up to see all 3 rounds

Series B through Series C — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Autobahn Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/autobahn-therapeutics"><img src="https://indexed.vc/api/badge/company/autobahn-therapeutics" alt="Autobahn Therapeutics on Indexed.vc" width="260" height="76" /></a>